A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)

ClinicalTrials.gov ID: NCT02019940

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02019940. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Investigation of the Effects of Riluzole in Patients With Post-Traumatic Stress Disorder (PTSD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This open label study will evaluate the safety and efficacy of riluzole in patients with PTSD. Patients will receive riluzole 50mg twice per day orally for 12 weeks as outpatient, with a one month follow up at week 16.

Study identification

NCT ID: NCT02019940
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Yale University; Other
Enrollment: 18 participants

Conditions and interventions

Conditions

PTSD

Interventions

Riluzole Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2014 (Type not available)
Primary completion: Jan 2020 (Actual)
Completion: Jan 2020 (Actual)
Last update posted: Apr 1, 2020

2014 – 2020

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Clinical Neuroscience Division, National Center for PTSD	West Haven	Connecticut	06516	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02019940, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 1, 2020 · Synced Nov 15, 2026